Kingswood Wealth Advisors LLC Sells 2,771 Shares of Eli Lilly and Company $LLY

Key Points

• Kingswood Wealth Advisors LLC reduced its stake in Eli Lilly and Company by 29.9%, selling 2,771 shares, and now owns 6,483 shares valued at $5,053,000.
• Several brokerages have recently changed their ratings on Eli Lilly, with the average rating now at "Moderate Buy" and an average price target of $938.94.
• Insider transactions indicate confidence in the company, with executives acquiring a total of 4,514 shares worth approximately $2.9 million over the past three months.

Kingswood Wealth Advisors LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 29.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,483 shares of the company's stock after selling 2,771 shares during the period. Kingswood Wealth Advisors LLC's holdings in Eli Lilly and Company were worth $5,053,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of LLY. WestEnd Advisors LLC lifted its stake in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after acquiring an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company during the first quarter worth $27,000. Citizens National Bank Trust Department grew its position in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $40,000. Finally, TD Capital Management LLC lifted its position in Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company's stock worth $46,000 after buying an additional 31 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on LLY. Leerink Partners restated a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. DZ Bank upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Wall Street Zen cut shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 20th. Finally, Cantor Fitzgerald dropped their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company's stock. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average price target of $938.94.

Insiders Place Their Bets

In other news, EVP Daniel Skovronsky acquired 1,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock worth $2,894,841 over the last three months. 0.14% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Price Performance

Shares of LLY opened at $845.40 on Tuesday. The company's 50-day moving average is $735.35 and its 200-day moving average is $765.48. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm has a market capitalization of $800.14 billion, a PE ratio of 55.25, a PEG ratio of 1.17 and a beta of 0.47. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the business posted $3.92 earnings per share. The business's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.